Table 1 The demographics, clinical characteristic and laboratory findings of urticaria patients compared to the control group
Group/Parameter | Acute urticaria (n = 32) | Chronic urticaria (n = 32) | Control group (n = 40) | |
|---|---|---|---|---|
Median age (yr) (Q25 – Q75) | 9.21 (7.04–12.13) | 11.21 (8–14.42) | 11 (7–14) | |
Range (yr) | 2–17 | 2–17 | 3–17 | |
Gender (M/F) | 17/15 | 13/19 | 21/19 | |
BMI (kg/m2) (Q25 – Q75) | 17.85 (15.74–21.84) | 18.39 (15.99–21.67) | 17.35 (16.15–19.88) | |
Median duration of hospitalization (days) (Q25 – Q75) | 5 (4–6) | 4 (3–5) | Not applicable (NA) | |
Localization of skin changes, n(%) | ||||
- whole body | 14 (43.8) | 6 (18.8) | ||
- limbs | 6 (18.8) | 8 (25) | ||
- trunck | 3 (9.4) | 7 (21.9) | ||
- trunck and limbs | 4 (12.5) | 8 (25.0) | ||
- face | 5 (15.6) | 3 (9.4) | ||
Edema of the limbs/arthritis, n(%) | 15 (46.9) | 2 (6.3) | ||
Angioedema, n(%) | 9 (28.1) | 5 (15.6) | ||
Fever > 38 °C, n(%) | 10 (31.2) | 0 | ||
Abdominal pain, n(%) | 4 (12.5) | 0 | ||
Wheezing, n(%) | 3 (9.4) | 1 (3.1) | ||
Respiratory tract infection, n(%) | 21 (65.6) | 4 (12.5) | ||
Other infections, n(%) | 3 (9.4) | 3 (9.4) | ||
Parasitic infection, n(%) | 3 (9.4) | 3 (9.4) | ||
Allergic disease, n(%)a | 10 (31.2) | 9 (28.1) | ||
Familial atopy, n(%) | 3 (9.4) | 13 (40.6) | ||
Antibiotic therapy, n(%) | 6 (18.8) | 0 | ||
Use of NSAIDs, n(%) | 2 (6.3) | 1 (3.1) | ||
Unknown cause, n(%) | 7 (21.9) | 14 (43.8) | ||
Concomitant diseases, n(%) | 21 (65.6) | 17 (53.1) | ||
- asthma | 1 (3.1) | 3 (9.4) | ||
- atopic dermatitits | 2 (6.3) | 4 (12.5) | ||
- allergic rhinitis | 3 (9.4) | 2 (6.3) | ||
- chronic tonsillitis/tonsillar hyperthrophy | 15 (46.9) | 8 (25.0) | ||
Severity score TSS, n (%) | ||||
Mild (0–3 points) | 3 (9.4) | 14 (43.8) | ||
Moderate (4–6 points) | 16 (50.0) | 8 (25.0) | ||
Severe (7–9 points) | 13 (40.6) | 10 (31.2) | ||
Medians of laboratory data (Q25 – Q75): | ||||
Hemoglobin (g/dL) | 12.76 (12.05–13.4)** | 13.63 (12.9–14.51) * | 12.88 (12.21–13.81) | |
Platelets (× 103/uL) | 348.5 (273.0–440.0)* | 327.0 (271.0–377.5)* | 274.5 (223–321) | |
White blood cells (× 103/uL) | 11.18 (7.6–15.63)*/** | 7.21 (5.9–9.24) | 6.65 (5.59–7.92) | |
Neutrophil (× 103/uL) | 6.44 (3.94–10.95)*/** | 3.5 (2.72–5.37) | 3.25 (2.31–3.84) | |
Lymphocyte (× 103/uL) | 2.8 (2.13–3.54) | 2.48 (2.1–3.38) | 2.22 (1.85–3.04) | |
Neutrophil-to-lymphocyte ratio (NLR) | 2.08 (1.69–3.35)*/** | 1.33 (0.87–2.2) | 1.22 (0.98–1.87) | |
Platelet-to-lymphocyte ratio (PLR) | 125.28 (81.58–160.45) | 119.56 (94.97–153.02) | 118.87 (84.81–145.27) | |
C-reactive protein (mg/l) | 7.66 (1.02–17.5)* | 1.14 (0.55–6.44)* | 0.6 (0.34–1.09) | |
Total IgE (IU/ml) | 74.21 (44.21–171.1) | 74.41 (26.46–191.55) | 33.87 (20.21–89.9) | |
D-dimer (ng/ml) | 1410.0 (690.0–2390.0)** | 270.0 (260.0–390.0) | Not applicable (NA) | |